Siderophore-harboring gut bacteria and fecal siderophore genes for predicting the responsiveness of fecal microbiota transplantation for active ulcerative colitis

• Published in: Journal of translational medicine Vol. 22; no. 1; pp. 589 - 12
• Main Authors: Yan, Jingshuang, Zhou, Guanzhou, Ren, Rongrong, Zhang, Xiaohan, Zhang, Nana, Wang, Zikai, Peng, Lihua, Yang, Yunsheng
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 24.06.2024; BioMed Central; BMC
• Subjects: Adult; Bacteria - genetics; Care and treatment; Clinical response; Colitis, Ulcerative - genetics; Colitis, Ulcerative - microbiology; Colitis, Ulcerative - therapy; Fecal Microbiota Transplantation; Feces - microbiology; Female; Gastrointestinal Microbiome - genetics; Gene Dosage; Genes, Bacterial; Genetic aspects; Humans; Male; Microbiota (Symbiotic organisms); Middle Aged; Physiological aspects; Prognosis; ROC Curve; Siderophore genes; Siderophores (Microbiology); Siderophores - metabolism; Treatment Outcome; Ulcerative colitis; China; Siderophore genes; Clinical response; Fecal microbiota transplantation; Ulcerative colitis
• ISSN: 1479-5876; 1479-5876
• DOI: 10.1186/s12967-024-05419-w

Predictive markers for fecal microbiota transplantation (FMT) outcomes in patients with active ulcerative colitis (UC) are poorly defined. We aimed to investigate changes in gut microbiota pre- and post-FMT and to assess the potential value in determining the total copy number of fecal bacterial siderophore genes in predicting FMT responsiveness. Patients with active UC (Mayo score ≥ 3) who had undergone two FMT procedures were enrolled. Fecal samples were collected before and 8 weeks after each FMT session. Patients were classified into clinical response and non-response groups, based on their Mayo scores. The fecal microbiota profile was accessed using metagenomic sequencing, and the total siderophore genes copy number via quantitative real-time polymerase chain reaction. Additionally, we examined the association between the total siderophore genes copy number and FMT efficacy. Seventy patients with UC had undergone FMT. The clinical response and remission rates were 50% and 10% after the first FMT procedure, increasing to 72.41% and 27.59% after the second FMT. The cumulative clinical response and clinical remission rates were 72.86% and 25.71%. Compared with baseline, the response group showed a significant increase in Faecalibacterium, and decrease in Enterobacteriaceae, consisted with the changes of the total bacterial siderophore genes copy number after the second FMT (1889.14 vs. 98.73 copies/ng, P < 0.01). Virulence factor analysis showed an enriched iron uptake system, especially bacterial siderophores, in the pre-FMT response group, with a greater contribution from Escherichia coli. The total baseline copy number was significantly higher in the response group than non-response group (1889.14 vs. 94.86 copies/ng, P < 0.01). A total baseline copy number cutoff value of 755.88 copies/ng showed 94.7% specificity and 72.5% sensitivity in predicting FMT responsiveness. A significant increase in Faecalibacterium, and decrease in Enterobacteriaceae and the total fecal siderophore genes copy number were observed in responders after FMT. The siderophore genes and its encoding bacteria may be of predictive value for the clinical responsiveness of FMT to active ulcerative colitis.